Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Luca Menilli
 -- 1200 2022-09-20 12:41:47 |
2 format correct
Conner Chen
Meta information modification 1200 2022-09-21 10:13:04 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Menilli, L.;  Milani, C.;  Reddi, E.;  Moret, F. Basic Principles and Mechanisms of Photodynamic Therapy. Encyclopedia. Available online: https://encyclopedia.pub/entry/27372 (accessed on 02 July 2024).
Menilli L,  Milani C,  Reddi E,  Moret F. Basic Principles and Mechanisms of Photodynamic Therapy. Encyclopedia. Available at: https://encyclopedia.pub/entry/27372. Accessed July 02, 2024.
Menilli, Luca, Celeste Milani, Elena Reddi, Francesca Moret. "Basic Principles and Mechanisms of Photodynamic Therapy" Encyclopedia, https://encyclopedia.pub/entry/27372 (accessed July 02, 2024).
Menilli, L.,  Milani, C.,  Reddi, E., & Moret, F. (2022, September 20). Basic Principles and Mechanisms of Photodynamic Therapy. In Encyclopedia. https://encyclopedia.pub/entry/27372
Menilli, Luca, et al. "Basic Principles and Mechanisms of Photodynamic Therapy." Encyclopedia. Web. 20 September, 2022.
Basic Principles and Mechanisms of Photodynamic Therapy
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14184462

Photodynamic therapy (PDT) is a therapeutic modality which uses visible light wavelengths, mainly in the red and near-infrared (NIR) regions, for the activation of photosensitizing molecules (PSs). The widespread diffusion of photodynamic therapy (PDT) as a clinical treatment for solid tumors is mainly limited by the patient’s adverse reaction (skin photosensitivity), insufficient light penetration in deeply seated neoplastic lesions, unfavorable photosensitizers (PSs) biodistribution, and photokilling efficiency due to PS aggregation in biological environments.

photodynamic therapy chemotherapy photosensitizers nanoparticles

1. Introduction

Photodynamic therapy (PDT) is a therapeutic modality which uses visible light wavelengths, mainly in the red and near-infrared (NIR) regions, for the activation of photosensitizing molecules (PSs). In the presence of molecular oxygen, light energy absorption by PSs triggers a sequence of events, ultimately leading to the formation of singlet oxygen (1O2) and other cytotoxic reactive oxygen species (ROS) [1]. Thus, any kind of cells or tissues in which a PS accumulates and that has been exposed to appropriate light wavelengths can be killed by irreversible damages caused by oxidative stress. This phototherapeutic approach has been largely investigated and proposed for the treatment of several pathological conditions, even if PDT is mainly applied in the oncology field for the treatment of selected types of solid tumors [2]. The first clinical studies of PDT in humans date back to the 1970s, while regulatory approval of PDT for the treatment of certain types of cancer dates back to the 1990s [3][4][5]. Many clinical trials have been completed and others are still ongoing, but PDT remains an underused modality for treating solid tumors, compared to conventional radiotherapy, surgery, or chemotherapy [6][7]. However, PDT is largely used in dermatology for the removal of non-melanoma skin cancers and the treatment of precancerous conditions such as actinic keratosis, being minimally invasive and with therapeutic efficacy comparable to surgery [8][9].
Limited light penetration into deep-sited tumor masses and poor oxygen availability can impair the efficacy of PDT. Even under this circumstance, its selectivity and absence of important side effects, if compared to chemotherapy, continues to stimulate the research of innovative approaches to overcome limitations, while fully exploiting PDT advantages. Despite recent successes in the clinical application of PDT, chemotherapy continues to remain the therapy of choice for the treatment of most cancers due to its high potential to eradicate cancer cells. However, chemotherapy is a very aggressive treatment with severe side effects. For this reason, current research in the oncology field is focusing on developing combinations of PDT and chemotherapy, with the aim to achieve a synergistic effect between the two therapies. These multi-therapeutic strategies could provide a way to reduce the recommended doses of chemotherapeutics, while at the same time overcoming the limitations of PDT. The advantages derived from this combinatorial approach can be better exploited by adopting strategies for delivering combinations of drugs selectively into tumor, concomitantly minimizing undesired side effects in normal tissues. Recent studies are mainly directed toward the design and realization of smart nanocomplexes and nanoplatforms to deliver PSs in combination with additional anticancer agents to optimize the efficiency and selectivity of drugs uptake into malignancies and to potentiate the overall anticancer responses.

2. Basic Principles and Mechanisms of Photodynamic Therapy

As anticipated, PDT is a strategy for treating tumors based on three components (light, PS, and molecular oxygen), neither of which is per se harmful to cells, but whose interplay triggers the formation of ROS that, above a given threshold, causes severe/lethal cell damages. The PDT starts with a systemic administration of the PS (or topical in the case of skin cancers); after a selected time, which allows the PS accumulation in the neoplastic lesion, the tumor mass is irradiated with light wavelengths absorbed by the PS, leading to the production of ROS. Commonly used PSs produce mainly 1O2, whose lifetime in biological environments is ~4 µs, with a corresponding diffusion radius in the tissue of no more than ~220 nm [10][11]. This implies that the photooxidative stress induced by PDT remains confined to the cells and tissue in which the PS has been accumulated and activated, thus conferring intrinsic selectivity to the therapy. Most of the PSs are macrocyclic molecules such as porphyrins or their derivatives, such as chlorins, bacteriochlorins, and phthalocyanines. All these molecules absorb light in the red and far-red regions of the visible spectrum, the so-called “PDT therapeutic window” (660–800 nm). In this spectral range, tissues are more transparent due to the limited light absorption of endogenous chromophores, thus allowing deeper light penetration [1].
ROS produced during PDT treatment are harmful to cells and organisms, because they oxidize a variety of biological components, with proteins and membrane lipids being the major targets [12]. Because of the short diffusion capacity of ROS, the primary damaged cellular sites are determined by the intracellular localization of the PS during light irradiation, which in turn depends on the physico-chemical features of the PS. In general, hydrophobic PSs mainly localize in the intracellular membranes of endoplasmic reticulum (ER), Golgi apparatus and mitochondria, while the hydrophilic ones are mainly found in endosomes and lysosomes [13][14]. However, the intracellular localization of a PS is determined also by additional parameters, such as incubation time and cell type [15][16]. Depending on the PS localization and on the primary sites of photodamage, different cellular responses can be triggered by PDT. In particular, if the oxidative insult exceeds the cellular capacity to restore homeostasis, cell death can occur mainly via necrosis, apoptosis, or autophagy [17][18] or via less known PDT-induced cell death pathways, such as necroptosis [19][20], ferroptosis [21], and parthanatos [22][23]. It has been well characterized that high PSs and light doses cause heavy cellular damages and induce accidental necrosis, similar to PSs that are associated with the plasma membrane, which cause oxidative stress to proteins and phospholipids. This results in rapid loss of membrane integrity and subsequent cell lysis [15][24]. On the contrary, low PDT doses and PSs localized in mitochondria, ER, or lysosomes lead to apoptosis, which is induced by direct damages to the anti-apoptotic proteins Bcl2 and Bcl-xL, without affecting the pro-apoptotic protein Bax [25]. Damage-associated molecular patterns (DAMPs or alarmins) are released by or exposed on the surface of dying cancer cells. DAMPs are perceived as “alarm signals” and stimulate a specific anti-tumor response to the PDT-treated tumor as well as distal untreated metastasis [26][27]. Thus, PDT can inhibit tumor growth by the direct killing of cancer cells through one of the mechanisms outlined above and subsequent activation of innate and adaptative immunity [28][29][30].
PDT can also damage and affect the functionality of components of the tumor microenvironment (TME), which often plays a fundamental role in favoring cancer cell proliferation, tumor progression, and development of drug resistance [31]. As an example, disorganized and hyperpermeable tumor vasculature sustains rapid cancer cell proliferation with oxygen and nutrients supply. Tumor vessels are important targets of PDT, as they are easily affected by oxidative stress, thus resulting in vessel constriction, damages to endothelial cells, thrombi formation, and ultimately complete stasis of the blood flow, leading to severe hypoxia and tumor necrosis. In general, with PDT protocols based on short drug-light intervals, in which light is delivered to tumor when high PS levels are still circulating in the bloodstream, the vasculature represents the main target of the treatment, while cancer cells are killed indirectly through oxygen and nutrient deprivation [32].

References

  1. Benov, L. Photodynamic Therapy: Current Status and Future Directions. Med. Princ. Pract. 2015, 24, 14–28.
  2. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic Therapy of Cancer: An Update. CA Cancer J. Clin. 2011, 61, 250–281.
  3. Kelly, J.F.; Snell, M.E. Hematoporphyrin Derivative: A Possible Aid in the Diagnosis and Therapy of Carcinoma of the Bladder. J. Urol. 1976, 115, 150–151.
  4. Dougherty, T.J.; Kaufman, J.E.; Goldfarb, A.; Weishaupt, K.R.; Boyle, D.; Mittleman, A. Photoradiation Therapy for the Treatment of Malignant Tumors. Cancer Res. 1978, 38, 2628–2635.
  5. Hamblin, M.R. Photodynamic Therapy for Cancer: What’s Past Is Prologue. Photochem. Photobiol. 2020, 96, 506–516.
  6. Li, X.; Lovell, J.F.; Yoon, J.; Chen, X. Clinical Development and Potential of Photothermal and Photodynamic Therapies for Cancer. Nat. Rev. Clin. Oncol. 2020, 17, 657–674.
  7. Alsaab, H.O.; Alghamdi, M.S.; Alotaibi, A.S.; Alzhrani, R.; Alwuthaynani, F.; Althobaiti, Y.S.; Almalki, A.H.; Sau, S.; Iyer, A.K. Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine. Cancers 2020, 12, 2793.
  8. Morton, C.A.; Szeimies, R.-M.; Sidoroff, A.; Braathen, L.R. European Guidelines for Topical Photodynamic Therapy Part 1: Treatment Delivery and Current Indications—Actinic Keratoses, Bowen’s Disease, Basal Cell Carcinoma. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 536–544.
  9. Fu, C.; Kuang, B.-H.; Qin, L.; Zeng, X.-Y.; Wang, B.-C. Efficacy and Safety of Photodynamic Therapy with Amino-5-Laevulinate Nanoemulsion versus Methyl-5-Aminolaevulinate for Actinic Keratosis: A Meta-Analysis. Photodiagnosis Photodyn. Ther. 2019, 27, 408–414.
  10. Redmond, R.W.; Kochevar, I.E. Spatially Resolved Cellular Responses to Singlet Oxygen. Photochem. Photobiol. 2006, 82, 1178–1186.
  11. Skovsen, E.; Snyder, J.W.; Lambert, J.D.C.; Ogilby, P.R. Lifetime and Diffusion of Singlet Oxygen in a Cell. J. Phys. Chem. B 2005, 109, 8570–8573.
  12. Bacellar, I.; Tsubone, T.; Pavani, C.; Baptista, M. Photodynamic Efficiency: From Molecular Photochemistry to Cell Death. Int. J. Mol. Sci. 2015, 16, 20523–20559.
  13. Kessel, D. Subcellular Targeting as a Determinant of the Efficacy of Photodynamic Therapy. Photochem. Photobiol. 2017, 93, 609–612.
  14. Moserova, I.; Kralova, J. Role of ER Stress Response in Photodynamic Therapy: ROS Generated in Different Subcellular Compartments Trigger Diverse Cell Death Pathways. PLoS ONE 2012, 7, e32972.
  15. Fabris, C.; Valduga, G.; Miotto, G.; Borsetto, L.; Jori, G.; Garbisa, S.; Reddi, E. Photosensitization with Zinc (II) Phthalocyanine as a Switch in the Decision between Apoptosis and Necrosis. Cancer Res. 2001, 61, 7495–7500.
  16. Hsieh, Y.-J.; Wu, C.-C.; Chang, C.-J.; Yu, J.-S. Subcellular Localization of Photofrin® Determines the Death Phenotype of Human Epidermoid Carcinoma A431 Cells Triggered by Photodynamic Therapy: When Plasma Membranes Are the Main Targets. J. Cell. Physiol. 2003, 194, 363–375.
  17. Kessel, D.; Oleinick, N.L. Cell Death Pathways Associated with Photodynamic Therapy: An Update. Photochem. Photobiol. 2018, 94, 213–218.
  18. Kessel, D.; Reiners, J.J. Photodynamic Therapy: Autophagy and Mitophagy, Apoptosis and Paraptosis. Autophagy 2020, 16, 2098–2101.
  19. Miki, Y.; Akimoto, J.; Moritake, K.; Hironaka, C.; Fujiwara, Y. Photodynamic Therapy Using Talaporfin Sodium Induces Concentration-Dependent Programmed Necroptosis in Human Glioblastoma T98G Cells. Lasers Med. Sci. 2015, 30, 1739–1745.
  20. Zhang, Y.; Cheung, Y.-K.; Ng, D.K.P.; Fong, W.-P. Immunogenic Necroptosis in the Anti-Tumor Photodynamic Action of BAM-SiPc, a Silicon(IV) Phthalocyanine-Based Photosensitizer. Cancer Immunol. Immunother. 2021, 70, 485–495.
  21. Shui, S.; Zhao, Z.; Wang, H.; Conrad, M.; Liu, G. Non-Enzymatic Lipid Peroxidation Initiated by Photodynamic Therapy Drives a Distinct Ferroptosis-like Cell Death Pathway. Redox Biol. 2021, 45, 102056.
  22. Soriano, J.; Mora-Espí, I.; Alea-Reyes, M.E.; Pérez-García, L.; Barrios, L.; Ibáñez, E.; Nogués, C. Cell Death Mechanisms in Tumoral and Non-Tumoral Human Cell Lines Triggered by Photodynamic Treatments: Apoptosis, Necrosis and Parthanatos. Sci. Rep. 2017, 7, 41340.
  23. Donohoe, C.; Senge, M.O.; Arnaut, L.G.; Gomes-da-Silva, L.C. Cell Death in Photodynamic Therapy: From Oxidative Stress to Anti-Tumor Immunity. Biochim. Et Biophys. Acta (BBA)—Rev. Cancer 2019, 1872, 188308.
  24. Mroz, P.; Yaroslavsky, A.; Kharkwal, G.B.; Hamblin, M.R. Cell Death Pathways in Photodynamic Therapy of Cancer. Cancers 2011, 3, 2516–2539.
  25. Xue, L.; Chiu, S.; Oleinick, N.L. Photochemical Destruction of the Bcl-2 Oncoprotein during Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4. Oncogene 2001, 20, 3420–3427.
  26. Thong, P.S.-P.; Ong, K.-W.; Goh, N.S.-G.; Kho, K.-W.; Manivasager, V.; Bhuvaneswari, R.; Olivo, M.; Soo, K.-C. Photodynamic-Therapy-Activated Immune Response against Distant Untreated Tumours in Recurrent Angiosarcoma. Lancet Oncol. 2007, 8, 950–952.
  27. Morrison, S.A.; Hill, S.L.; Rogers, G.S.; Graham, R.A. Efficacy and Safety of Continuous Low-Irradiance Photodynamic Therapy in the Treatment of Chest Wall Progression of Breast Cancer. J. Surg. Res. 2014, 192, 235–241.
  28. Hwang, H.S.; Shin, H.; Han, J.; Na, K. Combination of Photodynamic Therapy (PDT) and Anti-Tumor Immunity in Cancer Therapy. J. Pharm. Investig. 2018, 48, 143–151.
  29. Zhang, Y.; Cheung, Y.-K.; Ng, D.K.P.; Fong, W.-P. Enhancement of Innate and Adaptive Anti-Tumor Immunity by Serum Obtained from Vascular Photodynamic Therapy-Cured BALB/c Mouse. Cancer Immunol. Immunother. 2021, 70, 3217–3233.
  30. Anand, S.; Govande, M.; Yasinchak, A.; Heusinkveld, L.; Shakya, S.; Fairchild, R.L.; Maytin, E.V. Painless Photodynamic Therapy Triggers Innate and Adaptive Immune Responses in a Murine Model of UV-induced Squamous Skin Pre-cancer. Photochem. Photobiol. 2021, 97, 607–617.
  31. Milla Sanabria, L.; Rodríguez, M.E.; Cogno, I.S.; Rumie Vittar, N.B.; Pansa, M.F.; Lamberti, M.J.; Rivarola, V.A. Direct and Indirect Photodynamic Therapy Effects on the Cellular and Molecular Components of the Tumor Microenvironment. Biochim. Et Biophys. Acta (BBA)—Rev. Cancer 2013, 1835, 36–45.
  32. Olivo, M.; Bhuvaneswari, R.; Lucky, S.S.; Dendukuri, N.; Soo-Ping Thong, P. Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-Faceted Anti-Tumor Modalities. Pharmaceuticals 2010, 3, 1507–1529.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology; Cell Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Luca Menilli
,
Celeste Milani
,
Elena Reddi
,
Francesca Moret
View Times: 446
Revisions: 2 times (View History)
Update Date: 21 Sep 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback